Drug Profile
Galcanezumab - Eli Lilly and Company
Alternative Names: Emgality; Galcanezumab-gnlm; LY-2951742Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Analgesics; Antimigraines; Monoclonal antibodies
- Mechanism of Action Calcitonin gene-related peptide antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Cluster headache; Migraine
- Discontinued Musculoskeletal pain
Most Recent Events
- 22 Apr 2023 Efficacy and adverse events data from a phase III PERSIST trial in Migraine presented at the 75th Annual Meeting of the American Academy of Neurology 2023 (AAN-2023)
- 27 Feb 2023 Eli Lilly has patent protection for galcanezumab in major European countries until 2033
- 17 Jan 2023 AffaMed Therapeutics obtains commercialization rights of galcanezumab from Eli Lilly and Company for the prevention of Migraine in Mainland China